Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
21 April 2021 - 9:30PM
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage
biopharmaceutical company on a mission to develop treatments that
restore cognitive function, today announced that Cheryl Gault,
Chief Operating Officer will present a corporate overview at B.
Riley’s Neuroscience Investor Conference on Thursday, April 29,
2021 at 1:00 p.m. ET. Cyclerion leaders will also be
available for one-on-one meetings at this conference and investors
may request a one-on-one meeting through B. Riley.
The live webcast can be accessed via the Investors & Media
section of the Cyclerion website at
https://ir.cyclerion.com/news-events/event-calendar. An
archived replay of the event will be available on the site for
approximately 90 days following the presentation.
About Cyclerion
Therapeutics Cyclerion Therapeutics is a
clinical-stage biopharmaceutical company on a mission to develop
treatments that restore cognitive function. Cyclerion’s lead
molecule is CY6463, a novel, first-in-class, CNS-penetrant, sGC
stimulator that modulates a key node in a fundamental CNS signaling
network. The multidimensional pharmacology elicited by the
stimulation of sGC has the potential to impact a broad range of CNS
diseases. CY6463 has shown rapid improvement in biomarkers
associated with cognitive function and is currently in clinical
development for Alzheimer's Disease with Vascular pathology (ADv)
and Mitochondrial Encephalomyopathy, Lactic Acidosis and
Stroke-like episodes (MELAS).
For more information about Cyclerion, please
visit https://www.cyclerion.com/ and follow us on Twitter
(@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
InvestorsCarlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
MediaAmanda SellersVerge Scientific
Communicationsasellers@vergescientific.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From May 2023 to May 2024